Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.53 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.53 |
| ▸ | TLR9 known ✓ | Q9NR96 | 1/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.62 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.62 |
| ▸ | ABAT | P80404 | 1/20 | 0.62 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.62 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | TYR | P14679 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.55 |
| ▸ | STAT3 | P40763 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL11482264 | 0.94 | TRPA1 (0.73) | TRPA1ALDH1A1HPGDTDP1TRIM24 | |
| SCHEMBL54199 | 0.91 | TRPA1 (1.00) | TRPA1ALDH1A1HPGDTDP1TRIM24 | |
| SCHEMBL901218 | 0.91 | TRPA1 (1.00) | TRPA1ALDH1A1HPGDTDP1TRIM24 | |
| SCHEMBL29452839 | 0.91 | TRPA1 (1.00) | TRPA1ALDH1A1HPGDTDP1TRIM24 | |
| Methyl Alcohol SCHEMBL27907460 | 0.90 | TRPA1 (0.96) | TRPA1ALDH1A1HPGDTDP1TRIM24 | |
| Sulfuric Acid SCHEMBL18825677 | 0.87 | ALDH1A1 (0.62) | TRPA1ALDH1A1TDP1ALOX5CYP1A2 | |
| SCHEMBL170629 | 0.85 | TRPA1 (0.86) | TRPA1ALDH1A1HPGDTDP1TRIM24 | |
| Ethylene Glycol SCHEMBL3792165 | 0.85 | TRPA1 (0.86) | TRPA1ALDH1A1HPGDTDP1TRIM24 | |
| Vanillin SCHEMBL1943810 | 0.85 | ALDH1A1 (0.86) | TRPA1ALDH1A1HPGDTDP1TRIM24 | |
| Vanillin SCHEMBL28058713 | 0.85 | ALDH1A1 (0.86) | TRPA1ALDH1A1HPGDTDP1TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| CN-118435054-A | Compositions and methods for diagnosing and treating chronic kidney disease | 雀巢产品有限公司 | 2024-08-02 | — | — | CN | claimed |
| WO-2023126758-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2023-07-06 | — | — | WO | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20260034086-A1 | Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis | HILL'S PET NUTRITION, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | disclosed |
| US-12458617-B2 | Pet food compositions comprising caprylic acid and docosahexaenoic acid and/or eicosapetaenoic acid for use in treating struvite urolithiasis | HILL'S PET NUTRITION, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20240424137-A1 | Biomarkers For Lysosomal Storage Diseases | AMICUS THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | disclosed |
| EP-4413376-A1 | BIOMARKERS FOR LYSOSOMAL STORAGE DISEASES | Amicus Therapeutics, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240257973-A1 | DISEASE SPECTRUM CLASSIFICATION | PATIENTSLIKEME LLC (US) | 2024-08-01 | — | — | US | disclosed |
| US-11894139-B1 | Disease spectrum classification | PATIENTSLIKEME LLC (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2023126758-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2023-07-06 | — | — | WO | disclosed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | disclosed |
| WO-2023060233-A1 | BIOMARKERS FOR LYSOSOMAL STORAGE DISEASES | AMICUS THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| US-20220202759-A1 | Pet Food Compositions Comprising Caprylic Acid and Docosahexaenoic Acid and/or Eicosapetaenoic Acid for Use in Treating Struvite Urolithiasis | HILL'S PET NUTRITION, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220102000-A1 | PREDICTING BLOOD METABOLITES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-03-31 | — | — | US | disclosed |
| US-20170370954-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | CYP27A1, LIPC, CYP46A1 | MAOA 2319/4885MAOB 1810/4885TLR9 3593/4885 |
| US-20260034086-A1 | Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis | FPR2, FPR1, FPR3 | MAOA 2258/4885MAOB 3013/4885TLR9 1082/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | MAOA 1233/4885MAOB 1784/4885TLR9 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.